Brian Rini, MD | Authors


Overview of a Phase III Trial of Pembrolizumab Plus Axitinib in RCC

July 13, 2017

Brian Rini, MD, professor of medicine, Cleveland Clinic, discusses the basis for the ongoing phase III KEYNOTE-426 trial, which is exploring pembrolizumab (Keytruda) plus axitinib (Inlyta) versus sunitinib (Sutent) alone in treatment-naive advanced metastatic renal cell carcinoma.

The Role of Cytoreductive Nephrectomy in Patients With Synchronous Metastases From RCC

February 11, 2014

Brian Rini, MD, associate professor, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, discusses the role of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma (RCC).